The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Pathways to Alzheimer's disease
Abstract
Recent trials of anti‐amyloid agents have not produced convincing improvements in clinical outcome in A lzheimer's disease; however, the reason for these poor or inconclusive results remains unclear. Recent genetic data continue to support the amyloid hypothesis of A lzheimer's disease with protective variants being found in the amyloid gene and both common low‐risk and rare high‐risk variants for disease being discovered in genes that are part of the amyloid response pathways. These data support the view that genetic variability in how the brain responds to amyloid deposition is a potential therapeutic target for the disease, and are consistent with the notion that anti‐amyloid therapies should be initiated early in the disease process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Self-citationHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Self-citationThe molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Self-citationInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Self-citationNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Self-citationA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Cited by
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Self-citationDementia in China: epidemiology, clinical management, and research advances
Jia, L., Quan, M., Fu, Y., Zhao, T., Li, Y., Wei, C., Tang, Y., Qin, Q., Wang, F., Qiao, Y., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30290-x · Cited by 875
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
Palmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400
β-amyloid Peptides and Amyloid Plaques in Alzheimer's Disease
Gouras, G. K., Olsson, T. T., & Hansson, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0313-y · Cited by 325
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans?
Franco, R., & Cedazo-Minguez, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00146 · Cited by 183
Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain
Wildburger, N. C., Esparza, T. J., LeDuc, R. D., Fellers, R. T., Thomas, P. M., Cairns, N. J., Kelleher, N. L., Bateman, R. J., & Brody, D. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-10422-x · Cited by 164
Tai, L. M., Ghura, S., Koster, K. P., Liakaite, V., Maienschein‐Cline, M., Kanabar, P., Collins, N., Ben‐Aissa, M., Lei, A. Z., Bahroos, N., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13072 · Cited by 165
Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition
Leonenko, G., Shoai, M., Bellou, E., Sims, R., Williams, J., Hardy, J., Escott‐Price, V., & Initiative, T. A. D. N. (2019) · Annals of Neurology · doi:10.1002/ana.25530 · Cited by 114
Self-citationLu, Q., Powles, R. L., Abdallah, S., Ou, D., Wang, Q., Hu, Y., Lu, Y., Liu, W., Li, B., Mukherjee, S., et al. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006933 · Cited by 97
TREM1 facilitates microglial phagocytosis of amyloid beta
Jiang, T., Zhang, Y.-D., Gao, Q., Zhou, J.-S., Zhu, X.-C., Lu, H., Shi, J.-Q., Tan, L., Chen, Q., & Yu, J.-T. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1622-5 · Cited by 91
Masitinib for the treatment of mild to moderate Alzheimer’s disease
Folch, J., Petrov, D., Ettcheto, M., Pedrós, I., Abad, S., Beas-Zarate, C., Lazarowski, A., Marin, M., Olloquequi, J., Auladell, C., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1045419 · Cited by 80
“First and foremost, the pharmaceutical industry and the broader scientific community have to be able to coherently answer the following questions: What are the reasons for the past failures of investigational drugs? Which class/classes of molecules may be more suitable for delaying AD pathology? How can effective neur…”
BackgroundTesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N. M., Scheltens, P., van der Flier, W. M., Huisman, M., Reinders, M. J. T., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01018-7 · Cited by 67
A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer’s disease
Sepulveda-Falla, D., Chavez-Gutierrez, L., Portelius, E., Vélez, J. I., Dujardin, S., Barrera-Ocampo, A., Dinkel, F., Hagel, C., Puig, B., Mastronardi, C., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02249-0 · Cited by 54
Self-citationA human brain vascular atlas reveals diverse cell mediators of Alzheimer’s disease risk
Yang, A. C., Vest, R. T., Kern, F., Lee, D. P., Maat, C. A., Losada, P. M., Chen, M. B., Agam, M., Schaum, N., Khoury, N., et al. (2021) · doi:10.1101/2021.04.26.441262 · Cited by 48
Gene Therapy Strategies for Alzheimer's Disease: An Overview
Alves, S., Fol, R., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.017 · Cited by 45
Quansah, M., David, M. A., Martins, R., El-Omar, E., Aliberti, S. M., Capunzo, M., Jensen, S. O., & Tayebi, M. (2025) · Healthcare · doi:10.3390/healthcare13010074 · Cited by 21
Reestablishing microglia function: good news for Alzheimer's therapy?
Biber, K. (2017) · The EMBO Journal · doi:10.15252/embj.201796627 · Cited by 3
Metadata
- Authors
- Hardy, J., Bogdanovic, N., Winblad, B., Portelius, E., Andreasen, N., Cedazo‐Minguez, A., & Zetterberg, H.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2014-01-27
- Volume
- 275
- Issue
- 3
- Pages
- 296-303
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2065678033
- Cited by
- 176
- References
- 31
- FWCI
- 15.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.